Exploring the Potential Drug Target (Biomarker) ATG7 (APG7L) (G10533)

Target Name: ATG7

NCBI ID: G10533

ATG7

Exploring the Potential Drug Target (Biomarker) ATG7 (APG7L)

ATG7 (APG7L) is a protein that is expressed in various tissues, including the brain, heart, and kidneys. It is a member of the ATG7 family, which is characterized by the presence of a unique nucleotide in the consensus transmembrane domain (N-terminus) of the protein. The ATG7 family has been implicated in various physiological processes, including cell signaling, inflammation, and neurodegeneration.

The search for potential drug targets and biomarkers has become a major focus in recent years, with many researchers investigating the function of ATG7 and its potential as a drug target. In this article, we will explore the potential drug target and biomarker that is ATG7 (APG7L).

The Structure and Function of ATG7

ATG7 is a 21-kDa protein that consists of a unique N-terminus, a transmembrane domain, and a C-terminus. The N-terminus of ATG7 contains a unique nucleotide, known as N1, which is shown in the figure below:

The N1 nucleotide is a modified form of adenine, which has a hydroxyl group (OH) at its 2'-position. This modification is known as \"methoxyadenine\" and has been shown to play a role in various cellular processes, including cell signaling and neurotransmission.

The transmembrane domain of ATG7 is characterized by the presence of a unique sequence that is conserved across various species. This domain is responsible for the protein's unique structure and function, as well as its ability to interact with various signaling pathways.

The C-terminus of ATG7 is a unique farnesylated cysteine residue, which is important for the protein's stability and localization to specific cellular compartments.

ATG7's Potential as a Drug Target

The unique structure and function of ATG7 have led to its potential as a drug target. Several studies have investigated the function of ATG7 and its potential as a drug target.

One of the main focuses of research has been the investigation of ATG7's role in neurodegeneration. Several studies have shown that ATG7 is involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition to its role in neurodegeneration, ATG7 has also been shown to be involved in various signaling pathways. For example, several studies have shown that ATG7 can interact with the protein p53, which is a well-known tumor suppressor protein. These interactions may play a role in the regulation of cellular processes that are important for human health and disease.

Another potential drug target for ATG7 is its role in inflammation. Several studies have shown that ATG7 is involved in the regulation of inflammatory responses, and that it can play a role in the development of various inflammatory diseases.

In conclusion, the unique structure and function of ATG7 make it an attractive drug target. Further research is needed to fully understand its potential role in various cellular processes and to develop effective therapies that target ATG7.

The Potential of ATG7 as a Biomarker

ATG7 is also a potential biomarker for various diseases. Its unique structure and function make it a valuable tool for the diagnosis and treatment of diseases associated with the regulation of cellular processes.

One of the main applications of ATG7 as a biomarker is its ability to interact with various signaling pathways. This makes it a potential target for diseases that are characterized by the regulation of cellular processes that are important for human health and disease.

For example,

Protein Name: Autophagy Related 7

Functions: E1-like activating enzyme involved in the 2 ubiquitin-like systems required for cytoplasm to vacuole transport (Cvt) and autophagy. Activates ATG12 for its conjugation with ATG5 as well as the ATG8 family proteins for their conjugation with phosphatidylethanolamine. Both systems are needed for the ATG8 association to Cvt vesicles and autophagosomes membranes. Required for autophagic death induced by caspase-8 inhibition. Facilitates LC3-I lipidation with phosphatidylethanolamine to form LC3-II which is found on autophagosomal membranes (PubMed:34161705). Required for mitophagy which contributes to regulate mitochondrial quantity and quality by eliminating the mitochondria to a basal level to fulfill cellular energy requirements and preventing excess ROS production. Modulates p53/TP53 activity to regulate cell cycle and survival during metabolic stress. Also plays a key role in the maintenance of axonal homeostasis, the prevention of axonal degeneration, the maintenance of hematopoietic stem cells, the formation of Paneth cell granules, as well as in adipose differentiation. Plays a role in regulating the liver clock and glucose metabolism by mediating the autophagic degradation of CRY1 (clock repressor) in a time-dependent manner (By similarity)

The "ATG7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATG7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets